- $3.92m
- -$3.70m
- $10.25m
- 36
- 71
- 17
- 36
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 12.16 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.67 | ||
| Price to Tang. Book | 0.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.34 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -84.48% | ||
| Return on Equity | -108.77% | ||
| Operating Margin | -43.17% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 1.62 | 2.51 | 5.18 | 10.25 | 15.86 | 25.23 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Directors
- Cam Garner NEC (72)
- David Gonyer PRE (57)
- Matthew D'Onofrio EVP (51)
- Marilyn Carlson OTH (73)
- Vickie Reed DRC
- Todd Brady IND (49)
- Malcolm Hill IND (64)
- Kenneth Widder IND
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- January 29th, 2007
- Public Since
- September 25th, 2013
- No. of Shareholders
- 9
- No. of Employees
- 3
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 1,492,858
- Address
- 420 Stevens Avenue, Suite 230, SOLANA BEACH, 92075
- Web
- https://evokepharma.com/
- Phone
- +1 8583451494
- Contact
- Daniel Kontoh-Boateng
- Auditors
- BDO USA, LLP
Upcoming Events for EVOK
Q3 2025 Evoke Pharma Inc Earnings Release
Similar to EVOK
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
Alpha Cognition
NASDAQ Capital Market
FAQ
What is the Evoke Pharma share price?
As of Today at 20:32 UTC, shares in Evoke Pharma are trading at $2.63. This share price information is delayed by 15 minutes.
How has the Evoke Pharma share price performed this year?
Shares in Evoke Pharma last closed at $2.63 and the price had moved by -56.34% over the past 365 days. In terms of relative price strength the Evoke Pharma share price has underperformed the S&P500 Index by -61.38% over the past year.
What are the analyst and broker recommendations for Evoke Pharma?
The overall consensus recommendation for Evoke Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Evoke Pharma dividend yield?
Evoke Pharma does not currently pay a dividend.
Does Evoke Pharma pay a dividend?
Evoke Pharma does not currently pay a dividend.
When does Evoke Pharma next pay dividends?
Evoke Pharma does not currently pay a dividend.
How do I buy Evoke Pharma shares?
To buy shares in Evoke Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Evoke Pharma?
As of the previous close price of $2.63, shares in Evoke Pharma had a market capitalisation of $3.92m.
Where are Evoke Pharma shares listed?
Here are the trading details for Evoke Pharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EVOK
What kind of share is Evoke Pharma?
Based on an overall assessment of its quality, value and momentum Evoke Pharma is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Evoke Pharma share price forecast for 2025?
The analyst consensus target price for shares in Evoke Pharma is $18.00. That is 585.14% above the last closing price of $2.63.
Analysts covering Evoke Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.01 for the next financial year.
Find out moreWhat is the trend in the Evoke Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Evoke Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -48.27%.
As of the last closing price of $2.63, shares in Evoke Pharma were trading -35.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Evoke Pharma PE Ratio?
The Evoke Pharma PE ratio based on its reported earnings over the past 12 months is 12.16. The shares last closed at $2.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Evoke Pharma?
Evoke Pharma's management team is headed by:
- Cam Garner - NEC
- David Gonyer - PRE
- Matthew D'Onofrio - EVP
- Marilyn Carlson - OTH
- Vickie Reed - DRC
- Todd Brady - IND
- Malcolm Hill - IND
- Kenneth Widder - IND